Quick Takeaways
- SANDS CAPITAL MANAGEMENT, LLC filed SCHEDULE 13G/A for Ultragenyx Pharmaceutical Inc. Common Stock, par value $0.001 per share (RARE).
- Disclosed ownership: 4.7%.
- Date of event: 31 Dec 2024.
SANDS CAPITAL MANAGEMENT, LLC - 31 Dec 2024 SCHEDULE 13G/A Report for Ultragenyx Pharmaceutical Inc. Common Stock, par value $0.001 per share (RARE)
- Filing Manager
- SANDS CAPITAL MANAGEMENT, LLC
- Reporting Manager
- SANDS CAPITAL MANAGEMENT, LLC
- Symbol
- RARE
- Shares outstanding
- 91,446,872 shares
- Disclosed Ownership
- 4,298,003 shares
- Ownership
- 4.7%
- Form type
- SCHEDULE 13G/A
- Filing time
- 12 Feb 2025, 11:42:47 UTC
- Date of event
- 31 Dec 2024
- SEC
- View on sec.gov
Quoteable Key Fact
"SANDS CAPITAL MANAGEMENT, LLC disclosed 4.7% ownership in Ultragenyx Pharmaceutical Inc. Common Stock, par value $0.001 per share (RARE) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 12 Feb 2025, 11:42.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| SANDS CAPITAL MANAGEMENT, LLC | 4.7% | 4,298,003 | 0 | 2,965,104 | /s/ Alexandra R. Fulk | Alexandra R. Fulk, Chief Compliance Officer, Senior Counsel | |
| SANDS FRANK M. | 4.7% | 4,298,003 | 0 | 2,965,104 | /s/ Frank M. Sands | Frank M. Sands |